Frog Gut Bacterium Ewingella americana Completely Eradicates Colon Tumors in Mice

The Japanese tree frog, Dryophytes japonicus, has become the source of a striking experimental cancer approach via a gut bacterium, Ewingella americana, that can completely eradicate colorectal tumors in mice. Amphibians and reptiles rarely develop cancer, so researchers systematically screened 45 bacterial strains from frogs, newts, and lizards; nine showed anti-tumor activity, but E. americana from the frog stood out by producing complete regressions after a single injection in mouse models. In immunocompetent mice with colorectal cancer, intravenous E. americana preferentially colonized the hypoxic tumor core, where most drugs and immune cells function poorly, exploiting its adaptation to low-oxygen environments that mimic tumor physiology.

Prostate tumors, especially high-grade and metastatic lesions, develop hypoxic regions that drive aggressiveness, treatment resistance, and immune evasion; hypoxia is a known contributor to radioresistance and castration resistance in prostate cancer. Bacteria that selectively colonize hypoxic tumor areas have been proposed as a broadly applicable platform across multiple solid tumors, and preclinical work with engineered Salmonella, Clostridium novyi-NT, and other strains supports activity in models beyond colon cancer, including prostate cancer xenografts and syngeneic systems. Conceptually, E. americana shares this hypoxia-targeting profile, so the same logic would extend to prostate tumors.
​
Once inside the tumor, the bacterium both damages cancer tissue directly and triggers strong immune activation, recruiting T cells, B cells, and neutrophils and turning “cold” tumors into inflamed, “hot” lesions. In these studies, a single dose of E. americana outperformed standard treatments such as doxorubicin and checkpoint blockade, and mice that were cured rejected a later re-challenge with cancer cells, indicating a vaccine-like, memory response. Short-term safety in mice looked acceptable: the bacteria were rapidly cleared from the bloodstream, did not persist in healthy organs, and did not cause obvious chronic toxicity under the experimental conditions.
​
However, E. americana is a known, though rare, opportunistic human pathogen, with documented cases of serious infection such as sepsis in immunocompromised patients, which raises important safety concerns for direct clinical translation. Future work will likely focus on attenuated or engineered strains, identification of the key anti-tumor molecules, and combination strategies with existing therapies, while expanding testing to additional tumor types and delivery routes. More broadly, this discovery supports the idea that underexplored microbiomes in amphibians and reptiles could be a rich source of novel cancer therapeutics, linking biodiversity conservation directly to drug discovery potential.

Source.